Originally published by our sister publication Infectious Disease Special Edition
By Ethan Covey
Patients who are naive to HIV pre-exposure prophylaxis (PrEP) and prescribed emtricitabine-tenofovir alafenamide (F/TAF; Descovy, Gilead) have a greater number of prescription dispenses, days supplied, and are less likely to discontinue or switch PrEP than those on emtricitabine-tenofovir disoproxil fumarate (F/TDF; Truvada, Gilead), according to a new study.
The study, which was presented at the 2022